Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine

BACKGROUND: This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials. METHODS: Immunogenicity data were analyzed from baseline and double-blind,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cephalalgia
Egile Nagusiak: Martinez, James M, Hindiyeh, Nada, Anglin, Greg, Kalidas, Kavita, Hodsdon, Michael E, Kielbasa, William, Moser, Brian A, Pearlman, Eric M, Garces, Sandra
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7469706/
https://ncbi.nlm.nih.gov/pubmed/32340471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102420920642
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak